Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is a Healthcare company (Biotechnology) with a market capitalization of $8.1B. The Maz Rating grades it against the other companies in its sector.
Protagonist Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $124.83, Protagonist Therapeutics, Inc. trades at 24.4x trailing earnings, 14.9x sales and 7.7x book value, with an EV/EBITDA of 21.8. Over the last twelve months it generated about $548M of revenue and $334M of net income. It runs a gross margin of 99.7%, an operating margin of 58.6% and a net margin of 62.0%. It shows return on equity of 42.8%, return on invested capital of 28.9% and a free cash flow yield of 1.3%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 19.85. Over the past 52 weeks the share price ranged from $77.00 to $160.81, with a beta of 1.79.
Protagonist Therapeutics, Inc. does not currently pay a dividend.
26 Wall Street analyst ratings cover the stock: 26 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Protagonist Therapeutics, Inc. (PTGX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 8.90% / 30% · Interest income / Revenue 3.01% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 8.53% / 33% · Receivables / Mkt Cap (36m) 3.06% / 49% · Interest income / Revenue 3.01% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 8.53% / 33.33% · Receivables / Mkt Cap (24m) 3.06% / 33.33% · Interest income / Revenue 3.01% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.14% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 79.4% / 33.33% · Receivables / Avg Assets (4Q) 10.6% / 33.33% · Interest income / Revenue 3.01% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 69.8% / 33.33% · (Cash+Recv) / Total Assets 94.8% / 33.33% · Interest income / Revenue 3.01% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Protagonist Therapeutics, Inc. (PTGX) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Protagonist Therapeutics, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 3.01% of each dividend: Protagonist Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.